



Toward a Universal Cancer Vaccine: Telomerase Reverse Transcriptase (hTERT) as the Core Antigen for Immunological Cancer Prevention

Ian Pranandi

Department of Biochemistry, School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta 14440, Indonesia

Citation: Ian Pranandi (2025) Toward a Universal Cancer Vaccine: Telomerase Reverse Transcriptase (hTERT) as the Core Antigen for Immunological Cancer Prevention. J. of Bio Adv Sci Research, 1(3):1-24. WMJ/JBASR-134

Abstract

Background: *The quest for a universal cancer vaccine represents one of the most ambitious goals in biomedical science. Among tumor-associated antigens, human telomerase reverse transcriptase (hTERT) stands out as an almost universal hallmark of malignancy, reactivated in more than 85% of human cancers but minimally expressed in normal somatic cells.*

Main Body: *This review synthesizes the molecular rationale, immunological mechanisms, and translational progress of hTERT-based vaccines. Telomerase biology reveals a compelling balance between tumor specificity and broad applicability, positioning hTERT as an ideal antigen for both therapeutic and preventive immunization. Clinical development has progressed through three generations, GV1001, GX301, and UV1, each improving immune activation, adjuvant formulation, and safety. Integration with checkpoint inhibitors, cytokine modulators, and novel delivery systems has further enhanced vaccine efficacy. Recent advances in bioinformatics and epitope engineering have enabled the construction of multi-epitope hTERT vaccines, offering broader HLA coverage and durable immunological memory.*

Future Directions: *As the field transitions toward cancer immunoprevention, hTERT vaccination may serve high-risk populations, such as individuals with hereditary cancer syndromes, chronic inflammation, or environmental exposure, by eliminating precancerous cells before malignant transformation. Future research should focus on overcoming immune tolerance, defining biomarkers of protection, and developing cost-effective, globally scalable vaccine platforms.*

Conclusions: *hTERT represents a scientifically grounded and translationally viable foundation for a universal cancer vaccine. By merging telomerase biology, immunoinformatics, and systems immunology, telomerase-based immunization has the potential to transform oncology from treatment toward prevention, heralding the era of cancer-free generations.*

***Corresponding author:** Ian Pranandi, Department of Biochemistry, School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta 14440, Indonesia. Email: ian.pranandi@atmajaya.ac.id

Keywords: hTERT, Telomerase, Universal Cancer Vaccine, Cancer Immunoprevention, Peptide Vaccine, Immunoinformatics, T-Cell Epitope, Tumor-Associated Antigen, Checkpoint Inhibitors, Preventive Oncology

Introduction

The Vision of Universal Cancer Immunoprevention Cancer remains one of the leading causes of morbidity and mortality worldwide, responsible for an estimated 10 million deaths annually [1]. Despite major advances in molecular diagnosis and targeted therapy, most cancers are still detected and treated at late stages, when curative interventions are limited and costly. Traditional prevention strategies, such as lifestyle modification, screening, and chemoprevention, have produced modest reductions in incidence, underscoring the need for more proactive biological approaches [2,3]. In this context, the concept of cancer immunoprevention has emerged as a transformative paradigm: using vaccines to elicit long-lasting immune protection against malignant transformation before it occurs [4,5].

Historically, the preventive success of vaccines against infection-associated cancers, most notably the hepatitis B virus (HBV) vaccine that reduces hepatocellular carcinoma risk and the human papillomavirus (HPV) vaccine that prevents cervical and oropharyngeal cancers, has validated the principle that immune priming can avert cancer development [6,7]. However, these vaccines act indirectly by preventing viral infection rather than targeting oncogenic mechanisms common to non-infectious cancers. The next frontier is the development of tumor-associated antigen-based vaccines capable of preventing or delaying spontaneous, non-viral cancers that arise from somatic mutations and dysregulated cellular proliferation [8,9].

Among potential universal antigens, telomerase reverse transcriptase (hTERT) stands out for its biological ubiquity and tumor specificity. Telomerase activation is a hallmark of cellular immortality, present in more than 85 percent of human malignancies but largely absent from most normal somatic tissues [10,11]. The selective reactivation of hTERT confers limitless replicative potential to cancer cells, making it an attractive target for immune recognition. Unlike

tissue-restricted antigens, hTERT's broad expression profile across tumor types supports the vision of a universal antigen that could form the backbone of a broadly protective vaccine [12,13].

The goal of hTERT-based immunoprevention is to train the immune system to recognize and eliminate pre-malignant cells expressing telomerase before they acquire full malignant potential [14]. Preclinical and clinical studies of hTERT-derived peptide vaccines, such as GV1001, GX301, and UV1, have demonstrated encouraging safety and immunogenicity, suggesting that telomerase-specific immunity can be induced without major toxicity. Recent progress in computational epitope prediction, adjuvant engineering, and immune checkpoint modulation further enhances the feasibility of designing affordable, precise, and population-adapted hTERT vaccines [15-17].

This review explores the scientific foundation and translational potential of telomerase-based cancer immunoprevention. It synthesizes current understanding of hTERT biology, immunogenicity, and vaccine development, evaluates the challenges inherent to targeting a self-derived antigen, and outlines a roadmap toward realizing a universal cancer vaccine that could fundamentally reshape cancer prevention strategies worldwide.

Telomerase Biology and hTERT Structure-Function Relationship

Telomerase is a ribonucleoprotein enzyme complex responsible for maintaining telomere length at the ends of eukaryotic chromosomes. Each round of DNA replication results in the progressive shortening of telomeres, a phenomenon that limits the replicative lifespan of somatic cells and contributes to cellular senescence. By counteracting this shortening, telomerase confers replicative immortality, a defining hallmark of cancer. Understanding its biology provides the foundation for recognizing human telomerase reverse transcriptase (hTERT) as a central molecular target for cancer immunoprevention [18-19].

Composition and Functional Role of the Telomerase Complex

Telomerase is composed of two core components:

- Telomerase reverse transcriptase (hTERT): the catalytic protein subunit responsible for synthesizing telomeric repeats.
- Telomerase RNA component (hTR or TERC): the RNA template that guides the addition of TTAGGG repeats to chromosomal ends.

Additional accessory proteins, such as dyskerin, NOP10, NHP2, and GAR1, stabilize the complex and regulate its assembly and nuclear localization. Through these coordinated interactions, telomerase elongates telomeres, ensuring genomic stability and chromosomal integrity, particularly in germline, stem, and certain proliferative immune cells [18-20].

Regulation of hTERT Expression

Unlike hTR, which is ubiquitously expressed, hTERT expression is the rate-limiting determinant of telomerase activity. In normal somatic cells, hTERT transcription is tightly repressed, whereas it is reactivated in over 85% of malignant cells. The hTERT promoter is highly regulated by multiple transcription factors, c-Myc, Sp1, NF- κ B, and ETS family proteins, which can activate transcription, while repressive factors such as Mad1, p53, and Menin suppress it [12,21].

Epigenetic mechanisms also play a pivotal role: promoter methylation and histone modifications modulate hTERT accessibility, while mutations in the promoter region (notably C228T and C250T) create de novo binding sites for transcriptional activators, further enhancing expression in several cancers such as melanoma and glioblastoma [11,22].

At the post-transcriptional level, alternative splicing generates catalytically inactive hTERT isoforms, potentially influencing immune recognition by altering epitope presentation. Collectively, this multilayered regulation underscores the fine balance between telomerase silencing in normal physiology and its aberrant activation in oncogenesis [12,23].

Structural Domains of hTERT and Their Functional Relevance

The hTERT protein comprises approximately 1,132 amino acids organized into four major domains:

1. TEN (Telomerase Essential N-terminal) domain: facilitates binding to single-stranded telomeric DNA and processivity of elongation.
2. TRBD (Telomerase RNA-Binding Domain): interacts with the RNA template (hTR) to position it correctly during nucleotide addition.
3. RT (Reverse Transcriptase) domain: contains conserved motifs essential for catalytic activity, including the YxDD motif characteristic of reverse transcriptases.
4. CTE (C-terminal Extension): stabilizes the holo-enzyme complex and influences nuclear trafficking [10-12,24].

From an immunological perspective, these domains harbor multiple linear and conformational epitopes that can be recognized by cytotoxic T lymphocytes. Notably, epitopes within the reverse transcriptase and C-terminal regions have been experimentally shown to elicit strong T-cell responses, making them prime candidates for peptide-based vaccine design [10-12,24].

Physiological and Pathological Roles of Telomerase
In normal physiology, telomerase activity is confined to germ cells, activated lymphocytes, and certain progenitor or stem cell populations, ensuring regenerative capacity without malignant transformation. Conversely, its reactivation in cancer cells enables limitless replication, genomic instability tolerance, and resistance to apoptosis. Moreover, telomerase contributes to non-canonical functions such as modulation of Wnt/ β -catenin signaling, mitochondrial protection, and oxidative stress resistance, all of which enhance tumor survival [11,25].

This dual nature, restricted expression in healthy tissues yet universal activation in cancer, provides the immunological selectivity necessary for safe vaccine targeting. In this way, hTERT represents not merely a biomarker of malignancy but a functional driver of tumor persistence, aligning biological necessity with therapeutic opportunity [14-15,26].

Implications for Vaccine Design

The molecular and structural features of hTERT directly inform epitope mapping and immunogen design.

The conserved nature of catalytic and RNA-binding domains allows for identification of cross-tumor epitopes that are both immunogenic and broadly applicable across diverse cancer types. Simultaneously, its low baseline expression in most somatic tissues reduces the risk of autoimmune cytotoxicity [11,12,27].

Thus, understanding telomerase biology and hTERT's structure–function relationship establishes the mechanistic rationale for using it as the core antigen in a universal cancer vaccine, bridging fundamental molecular oncology with translational immunology [13–15,27].

hTERT as a Universal Tumor Antigen

The concept of a universal tumor antigen refers to a molecule that is consistently overexpressed across diverse cancer types but remains minimally expressed in normal tissues, making it a broadly applicable and safe immunological target. Among all known tumor-associated antigens (TAAs), human telomerase reverse transcriptase (hTERT) uniquely fulfills these criteria. Its reactivation is nearly ubiquitous across human malignancies and intimately linked to the acquisition of cellular immortality, one of the most essential hallmarks of cancer. As such, hTERT has emerged as both a biomarker of malignant transformation and a versatile antigenic candidate for vaccine-based immunotherapy and immunoprevention [10–12,28].

Telomerase Reactivation Across Human Cancers

Extensive transcriptomic and proteomic analyses have confirmed that telomerase is reactivated in approximately 85–90% of human cancers, regardless of tissue origin or histological subtype. Elevated hTERT mRNA and protein levels have been documented in carcinomas (lung, breast, colorectal, pancreatic, hepatic), sarcomas, gliomas, leukemias, and melanomas, highlighting its near-universal role in sustaining tumor proliferation [12,29].

In contrast, telomerase activity in normal tissues is limited to germ cells, stem cells, and activated lymphocytes, where it supports regenerative potential without uncontrolled proliferation. This sharp dichotomy between malignant and normal expression provides a wide therapeutic window,

enabling immune targeting of hTERT with minimal risk to essential physiological functions. Moreover, because telomerase activation occurs early in tumorigenesis, hTERT serves as both a diagnostic biomarker and a potential preventive vaccine target capable of intercepting premalignant lesions before they achieve full malignancy [12,29–30].

Immunogenicity of hTERT-Derived Peptides

Although hTERT is a self-derived protein, it retains multiple immunogenic epitopes capable of eliciting both CD8⁺ cytotoxic and CD4⁺ helper T-cell responses. Numerous studies have identified naturally processed peptides derived from hTERT that are presented by common HLA class I alleles such as HLA-A02:01, HLA-A24:02, and HLA-B*07:02 [11,31].

Key examples include the hTERT (540–548), hTERT (572–580), and hTERT (865–873) epitopes, which have been shown to induce strong cytotoxic T-lymphocyte (CTL) activity against tumor cells in vitro and in clinical trials. In addition, HLA class II–restricted epitopes such as hTERT (611–626) and hTERT (660–689) stimulate helper T-cell activation and IFN- γ production, reinforcing CD8⁺ responses and facilitating immunological memory [12,32].

Importantly, telomerase-specific T cells have been detected spontaneously in the peripheral blood of cancer patients and, in some cases, even in healthy individuals, implying that the immune system can recognize and respond to telomerase-derived antigens under natural conditions. These findings collectively validate hTERT as an intrinsically immunogenic antigen suitable for both therapeutic and prophylactic vaccination strategies [11,32,33].

Evidence from Clinical Trials and Immune Monitoring

Clinical investigations using hTERT-derived peptide vaccines, such as GV1001, GX301, and UV1, have confirmed that hTERT epitopes can safely induce measurable immune responses in humans.

- GV1001, derived from amino acids 611–626 of hTERT, elicited multifunctional T-cell responses and showed immune memory lasting over a year in patients with pancreatic and lung cancer [15].
- GX301, a multi-peptide formulation combining four hTERT epitopes, demonstrated enhanced

CD4⁺ and CD8⁺ activation with minimal toxicity [16].

- UV1, composed of three synthetic long peptides derived from hTERT, is currently under phase II and III evaluation in melanoma, prostate, and non-small cell lung cancers, showing promising results when combined with immune checkpoint inhibitors [17].

Across these studies, telomerase-targeted vaccination has been well tolerated, with the most common adverse effects limited to mild injection-site reactions or transient flu-like symptoms. Importantly, no clinically significant autoimmunity or stem-cell toxicity has been observed, reinforcing the safety of targeting hTERT in humans [15-17].

Cross-Cancer and Population-Level Applicability

Unlike most TAAs that exhibit tumor-type specificity, hTERT's conserved expression pattern across virtually all cancers makes it uniquely suitable for broad-spectrum immunization. The antigenic epitopes of hTERT are highly conserved among diverse populations, allowing for vaccine designs that achieve wide HLA coverage, an essential feature for a globally applicable vaccine [14,34].

Moreover, since hTERT expression often precedes genomic instability and metastasis, a telomerase-targeted immune response has the potential to intercept tumor progression at early, pre-invasive stages. This feature distinguishes hTERT from other universal antigens such as MUC1 or survivin, whose overexpression tends to occur later during carcinogenesis. Thus, from both biological and immunological standpoints, hTERT is optimally positioned as a preventive target [13,35].

Integration of hTERT into the Concept of Universal Cancer Vaccination

The concept of a universal cancer vaccine aims to generate immune protection not against a single malignancy but across multiple tumor types by targeting shared molecular drivers of oncogenesis. hTERT embodies this ideal more completely than any other known antigen. Its universality ensures that a single antigenic construct could, in principle, provide protection against a vast array of cancers, while its limited expression in normal tissues minimizes the risk

of autoimmune complications [8,36].

In addition, hTERT-specific immunity may synergize with the body's existing surveillance mechanisms, enhancing clearance of cells undergoing early malignant transformation. For these reasons, telomerase-directed vaccination represents not only a therapeutic opportunity but also a scientifically grounded path toward the primary prevention of cancer, a vision that extends beyond organ-specific oncology into population-level immunological health [17,37].

Immunological Mechanisms of Telomerase-Directed Immunity

The ability of the immune system to recognize and eliminate neoplastic cells underlies the concept of cancer immunosurveillance. Within this framework, the reactivation of telomerase, particularly its catalytic subunit, hTERT, creates a distinct molecular signature that can be detected by both innate and adaptive immune mechanisms. Understanding how hTERT-derived antigens are processed, presented, and targeted by immune effector cells is essential for designing effective vaccines that harness or amplify these natural defense pathways.22,38

Antigen Processing and Presentation of hTERT-Derived Peptides

In tumor cells, overexpressed hTERT proteins are degraded by the ubiquitin-proteasome system, generating peptide fragments that are translocated into the endoplasmic reticulum via the TAP (transporter associated with antigen processing) complex. These peptides bind to MHC class I molecules and are subsequently presented on the cell surface, where they can be recognized by CD8⁺ cytotoxic T lymphocytes (CTLs) [19,39].

Parallel to this, professional antigen-presenting cells (APCs) such as dendritic cells can uptake tumor-derived hTERT antigens through endocytosis or cross-presentation, processing them for display on both MHC class I and II molecules. This dual presentation pathway facilitates the activation of both cytotoxic and helper T-cell subsets, providing a coordinated immune response against hTERT-expressing tumor cells [18,19,40].

CD8⁺ Cytotoxic T-Cell Responses

Cytotoxic T lymphocytes are the principal effectors of telomerase-specific tumor killing. Upon recognition of hTERT-derived peptides presented by MHC class I, CTLs become activated and exert their cytolytic activity through perforin–granzyme release, Fas–FasL interaction, and cytokine-mediated apoptosis of target cells [18,41].

Several hTERT epitopes have been shown to generate potent CTL responses in vitro and in vivo. For instance, the hTERT(540–548) and hTERT(865–873) peptides presented by HLA-A*02:01 molecules trigger high-avidity T cells capable of lysing a wide range of cancer cells, including those derived from lung, melanoma, and colon carcinomas. These antigen-specific CTLs not only destroy existing tumor cells but also establish immunological memory, a property essential for durable cancer immunoprevention [24,42].

CD4⁺ Helper T-Cell Responses and Immune Coordination

CD4⁺ T helper cells play a crucial role in sustaining CTL activation and shaping the cytokine milieu that dictates the quality of the anti-tumor response. hTERT-derived epitopes such as hTERT(611–626) and hTERT(660–689) are presented via MHC class II molecules, leading to the activation of Th1-polarized responses characterized by the secretion of interferon- γ (IFN- γ) and interleukin-2 (IL-2) [11,43].

These cytokines promote CTL proliferation, enhance antigen presentation, and recruit macrophages and natural killer (NK) cells to the tumor site. In addition, CD4⁺ T-cell help is essential for the development of long-lived CD8⁺ memory populations and the prevention of T-cell exhaustion, which frequently undermines therapeutic vaccine efficacy [12,44].

Therefore, optimal telomerase-targeted vaccines aim to include both class I-restricted and class II-restricted epitopes, ensuring synergistic activation of the adaptive immune network.^{43,44}

Role of the Innate Immune System and Adjuvants

The success of hTERT-directed immunity depends not only on adaptive T-cell responses but also on robust innate immune activation that provides the

necessary costimulatory signals. Pattern-recognition receptors such as Toll-like receptors (TLRs) on dendritic cells recognize adjuvants or danger-associated molecular patterns (DAMPs) co-delivered with the vaccine, inducing the secretion of type I interferons and proinflammatory cytokines [13,45].

This inflammatory environment upregulates MHC expression and costimulatory molecules (CD80/CD86), enhancing the priming of hTERT-specific T cells. Adjuvants like Montanide ISA-51, CpG oligodeoxynucleotides, and poly-ICLC have been shown to significantly amplify telomerase-specific immunity in clinical trials such as those involving GX301 and UV1 formulations [16,17,46].

These innate mechanisms form the immunological bridge that connects peptide recognition with effective T-cell-mediated tumor destruction [45,46].

Overcoming Immune Tolerance to a Self-Derived Antigen

Because hTERT is a self-protein, immune tolerance mechanisms, both central and peripheral, pose a natural barrier to effective vaccination. During thymic selection, high-avidity T cells recognizing ubiquitous self-antigens are deleted, leaving only low-affinity clones capable of weak recognition. This phenomenon limits the spontaneous generation of strong anti-hTERT responses in healthy individuals [10,47].

To circumvent this limitation, vaccine strategies employ heterologous prime-boost regimens, potent adjuvants, or modified peptide sequences that enhance antigenicity while maintaining safety. Furthermore, immune checkpoint inhibitors targeting PD-1 or CTLA-4 can release inhibitory brakes on T cells, restoring the functional activity of telomerase-specific clones. Early clinical data combining UV1 vaccination with checkpoint blockade demonstrate improved immunogenicity, highlighting a viable strategy to overcome tolerance and immune exhaustion [17,48].

Safety and Autoimmunity Considerations

An essential feature of telomerase-targeted immunity is its selective cytotoxicity toward malignant or highly proliferative cells expressing hTERT, with minimal damage to normal somatic tissues. Clinical evidence indicates that while telomerase is transiently active in

stem and germ cells, these populations are generally protected due to their immune-privileged niches and low antigen presentation [13,49].

Long-term follow-up from hTERT vaccine trials has not revealed significant autoimmune pathology or impairment of hematopoietic or reproductive function. Nonetheless, vigilance remains necessary in preventive applications where vaccines may be administered to healthy individuals. Safety optimization, through controlled epitope selection and adjuvant modulation, will be crucial for the transition from therapeutic to preventive use [13,50].

Immunological Memory and Long-Term Protection

The ultimate goal of telomerase-directed vaccination is the establishment of durable immunological memory capable of rapid recall upon reappearance of hTERT-expressing cells. Memory CD8⁺ and CD4⁺ T cells generated after peptide vaccination can persist for years, providing ongoing surveillance against latent or emerging neoplastic foci [41,51].

This sustained immunological vigilance offers a mechanistic explanation for how hTERT-based vaccines could serve as a foundation for cancer immunoprevention, maintaining a state of readiness that neutralizes early oncogenic events long before clinical cancer develops [50,51].

Summary

Telomerase-directed immunity integrates multiple immune mechanisms: efficient antigen presentation, coordinated activation of CD8⁺ and CD4⁺ T cells, innate immune priming, and long-term memory formation. The capacity to induce such responses safely against a self-derived but tumor-restricted antigen distinguishes hTERT from most other cancer targets. By exploiting these mechanisms, telomerase-based vaccines bridge molecular oncology and adaptive immunology, establishing a rational platform for the future of universal cancer immunoprevention [49-51].

Development of hTERT-Based Cancer Vaccines

The translation of telomerase biology into clinical immunotherapy has progressed steadily over the past two decades, establishing hTERT-based vaccines as one of the most extensively investigated classes of universal

cancer immunogens. Early experimental evidence demonstrating spontaneous hTERT-specific T-cell responses in cancer patients led to the rational design of peptide and multi-peptide formulations that mimic naturally processed telomerase epitopes. These formulations were optimized through successive generations of vaccines, ranging from single-epitope peptides to complex, adjuvant-enhanced platforms, each seeking to elicit stronger, broader, and more durable immune responses with minimal toxicity [14,52].

Early Milestone: The GV1001 Vaccine

GV1001 (611–626 peptide; sequence: EARPALLTSRLRFIPK) was the first hTERT-derived vaccine to enter clinical evaluation. Developed by GemVax & KAEL, it was designed as a 16-amino acid peptide corresponding to a class II HLA-binding region within the hTERT catalytic domain, with the ability to also stimulate class I-restricted CTLs through cross-presentation [15].

In multiple early-phase trials involving pancreatic, lung, and melanoma patients, GV1001 demonstrated robust induction of telomerase-specific CD4⁺ and CD8⁺ responses, often accompanied by IFN- γ secretion and proliferation of memory T cells. Although the initial phase III trial in advanced pancreatic cancer did not achieve a survival advantage over chemotherapy, immune monitoring confirmed long-lived T-cell activation, validating the feasibility of breaking tolerance to a self-antigen safely in humans [15].

Notably, GV1001 has also shown additional biological effects beyond vaccination: subsequent studies reported its ability to penetrate cell membranes and modulate intracellular signaling, opening potential avenues for adjunctive anti-inflammatory or anti-aging research [15].

The GX301 Multi-Peptide Vaccine

To enhance immune breadth and overcome HLA restriction, researchers developed GX301, a second-generation vaccine comprising four hTERT-derived peptides (540–548, 611–626, 672–686, and 766–780) combined with two adjuvants—Montanide ISA-51 (oil-based emulsion) and N-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium methyl sulfate (DOTAP), a cationic lipid facilitating antigen uptake [16].

GX301 was tested in patients with prostate, melanoma, and colorectal cancers. The results demonstrated polyfunctional T-cell responses covering both class I and class II epitopes, along with increased antibody titers and delayed-type hypersensitivity reactions indicative of *in vivo* immunogenicity. Importantly, GX301 vaccination resulted in minimal systemic toxicity and no evidence of autoimmunity [16].

This multi-epitope strategy addressed one of the major challenges of single-peptide vaccines, namely, inter-individual variability in HLA presentation, and laid the foundation for designing population-wide hTERT-based immunogens capable of broad immunological coverage [16].

Next-Generation Innovation: The UV1 Vaccine

UV1, developed by Ultimovacs, represents the third and most advanced generation of hTERT-targeted peptide vaccines. It consists of three synthetic long peptides (15–30 amino acids) derived from the active catalytic region of hTERT, designed to bind multiple HLA class II molecules. The long-peptide format allows uptake by professional antigen-presenting cells and efficient cross-presentation to both CD4⁺ and CD8⁺ T cells [17].

Unlike earlier formulations, UV1 is typically co-administered with granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjuvant to recruit and activate dendritic cells at the injection site. Clinical trials in malignant melanoma, non-small cell lung cancer, and prostate cancer have reported durable T-cell responses, favorable safety profiles, and encouraging efficacy when combined with checkpoint inhibitors such as nivolumab or pembrolizumab [17].

Notably, in the UV1–103 phase II trial, the combination of UV1 and pembrolizumab in advanced melanoma produced a two-year overall survival rate exceeding 70%, substantially higher than historical controls with checkpoint blockade alone. These findings provide clinical validation that hTERT vaccination can synergize with immune checkpoint inhibition, achieving stronger and more persistent anti-tumor immunity [17].

DNA, mRNA, and Viral Vector Platforms

Beyond peptide formulations, hTERT has also been incorporated into nucleic acid-based vaccines and viral vectors to enhance antigen delivery and expression.

- DNA vaccines encoding full-length or truncated hTERT sequences (e.g., pHERT, INVAC-1) have shown potent cellular responses in preclinical models and early clinical trials, inducing both Th1 cytokine profiles and CTL-mediated tumor inhibition [13,53].
- mRNA-based approaches, inspired by the success of COVID-19 mRNA vaccines, are currently under experimental development for telomerase antigens, offering improved manufacturability and precise epitope encoding [13,54].
- Viral vectors, such as modified vaccinia Ankara (MVA) and adenoviral constructs expressing hTERT, have demonstrated efficient *in vivo* antigen presentation, further broadening platform diversity [13,55].

These evolving platforms illustrate a progressive trend from synthetic peptides toward multimodal vaccine systems that combine safety, potency, and scalability, critical features for eventual prophylactic applications in healthy populations [13,53–55].

Comparative Insights and Lessons Learned

Collectively, the clinical trajectory of hTERT vaccines from GV1001 to UV1 reveals several key insights:

01. Safety: All formulations have exhibited favorable toxicity profiles with no significant autoimmune sequelae.
02. Immunogenicity: Inclusion of both class I and II epitopes, use of strong adjuvants, and long-peptide formats markedly improve immune activation.
03. Synergy with Checkpoint Blockade: The combination of telomerase vaccination and PD-1/CTLA-4 inhibition is emerging as a highly synergistic paradigm.
04. Durability: Telomerase-specific memory T cells can persist for years post-vaccination, supporting long-term immunosurveillance.
05. Limitations: Clinical benefit in advanced cancers remains modest, emphasizing the potential superiority of preventive or early-intervention applications over late-stage therapy [15–17].

Summary of Major hTERT Vaccine Candidates

Table 1: Key hTERT-Based Vaccine Candidates and Clinical Trial Summaries [15-17]

Vaccine	Composition / Target Region	Adjuvant	Cancer Types Tested	Clinical Phase	Key Findings
GV1001	16-mer peptide (611–626)	None or GM-CSF	Pancreatic, lung, melanoma	II–III	Safe, strong T-cell activation; limited efficacy in advanced disease
GX301	Four peptides (540–548, 611–626, 672–686, 766–780)	Montanide + DOTAP	Melanoma, prostate, CRC	I–II	Broad HLA coverage, high immunogenicity, low toxicity
UV1	Three long peptides from hTERT catalytic domain	GM-CSF	Melanoma, NS-CLC, prostate	II–III	Durable T-cell response, synergistic with checkpoint blockade
INVAC-1	DNA vaccine encoding full-length hTERT	Electroporation delivery	Multiple solid tumors	I	Potent Th1 response; well tolerated
MVA-hTERT	Modified vaccinia Ankara vector expressing hTERT	Intradermal	Preclinical / early clinical	Preclinical	Efficient antigen presentation, high CTL induction

Table 1 summarizes the key clinical and preclinical hTERT-based vaccine candidates that have shaped the evolution of telomerase-targeted immunotherapy. From the pioneering single-peptide GV1001, through the multi-peptide GX301, to the next-generation long-peptide UV1, each successive formulation demonstrates a refinement in antigen selection, adjuvant design, and immune activation profile. Collectively, these studies confirm the feasibility of inducing potent, durable hTERT-specific T-cell responses without triggering significant autoimmune toxicity. The inclusion of DNA- and viral-vector platforms further underscores the diversification of vaccine delivery strategies, providing the technological foundation for adapting hTERT vaccination from therapeutic to preventive applications across multiple cancer types [15-17].

The chronological development of hTERT-based cancer vaccines reflects the progressive refinement of telomerase-targeted immunotherapy over the past two decades. Figure 1 summarizes key milestones, beginning with the discovery of hTERT’s immunogenic epitopes in the late 1990s, followed by the introduction of GV1001 as the first clinical peptide vaccine. Subsequent advancements, including the multi-peptide GX301 formulation and the long-peptide UV1 platform, illustrate the strategic evolution from single-epitope prototypes to polyvalent and adjuvant-enhanced constructs capable of eliciting broader and more durable T-cell responses. The figure also highlights the diversification of delivery systems, such as DNA and viral vector vaccines (INVAC-1, MVA-hTERT), and the emergence of combination trials integrating hTERT vaccination with checkpoint blockade therapies. Collectively, this timeline captures how cumulative scientific and clinical insights have shaped telomerase-based vaccination into a mature, translationally viable field at the intersection of oncology and immunology [15-17].




Figure 1: Timeline of Major hTERT Vaccine Development Milestones (GV1001 – UV1) [15-17]

The timeline illustrates the scientific and clinical evolution of telomerase-based vaccine research, from the initial discovery of hTERT and its immunogenic epitopes to current combination strategies integrating telomerase vaccination with immune checkpoint blockade. Each milestone marks a key advance in platform technology, antigen formulation, or translational application, culminating in ongoing efforts to adapt hTERT vaccination for preventive use across multiple cancer types [15-17].

Outlook

The evolution of hTERT-based vaccines reflects a maturing understanding of tumor immunology, from single-epitope therapeutics to multi-epitope, adjuvanted, and combination strategies. As next-generation platforms emerge, the focus is shifting toward immunopreventive applications, vaccinating individuals at high risk of cancer development before malignant transformation occurs [14-56].

This shift represents not merely an extension of immunotherapy but a conceptual redefinition of oncology, from treatment to prevention through immune education. hTERT stands at the forefront of this paradigm, embodying the most promising antigenic candidate for a universal cancer vaccine [14-57].

hTERT Vaccines for Cancer Immunoprevention

The transition of telomerase-based vaccination from a therapeutic to a preventive strategy represents one of the most promising frontiers in oncology. Unlike immunotherapy, which aims to control or eradicate established malignancies, cancer immunoprevention seeks to educate the immune system before malignant transformation occurs, thereby intercepting early oncogenic events and maintaining tissue homeostasis. Telomerase, being reactivated in the vast majority of human cancers but largely dormant in normal somatic cells, constitutes an ideal immunological target for this proactive approach [12-14].

Conceptual Basis for Cancer Immunoprevention

The principle of cancer immunoprevention derives from decades of evidence supporting immune surveillance, the natural process by which the immune system identifies and eliminates nascent transformed cells. However, as tumor cells acquire immune evasion mechanisms, such as loss of antigen presentation or induction of T-cell exhaustion, this surveillance becomes insufficient. A vaccine capable of eliciting durable T-cell memory against an early, conserved antigen such as hTERT could restore this equilibrium, effectively preventing tumor emergence. Unlike infection-derived cancer vaccines (e.g., HPV and HBV), which target exogenous viral antigens, an hTERT-based preventive vaccine would act against an endogenous but malignancy-specific antigen, allowing universal application across cancer types. This approach could bridge the gap between classical vaccination and modern precision oncology [36,58].

Biological Rationale for Targeting hTERT in Prevention

hTERT reactivation occurs early in carcinogenesis, often preceding other genetic or epigenetic alterations that drive malignant progression. Elevated hTERT expression has been detected in precancerous lesions, such as cervical intraepithelial neoplasia, colonic adenomas, oral leukoplakia, and chronic hepatitis-associated dysplastic nodules, suggesting a window of opportunity for immune intervention before invasive disease develops [11,59].

Moreover, telomerase activity supports not only replicative immortality but also noncanonical oncogenic signaling, including activation of Wnt/ β -catenin and NF- κ B pathways, suppression of apoptosis, and maintenance of stem-like properties. By generating immunity against hTERT-expressing cells at this early stage, a preventive vaccine could block multiple oncogenic cascades simultaneously, achieving a multilayered barrier to tumorigenesis [33,60].

Potential Target Populations for Preventive Application

Preventive telomerase vaccination would be most beneficial for individuals with increased baseline cancer risk, where early intervention could significantly reduce morbidity and mortality. These populations include:

- Genetically predisposed individuals, such as carriers of BRCA1/2, APC, TP53, or MLH1/MSH2 mutations.
- Patients with chronic inflammatory or precancerous conditions, including chronic viral hepatitis, ulcerative colitis, Barrett's esophagus, or oral potentially malignant disorders.
- Elderly individuals or those with immunosenescence, in whom reduced immune surveillance contributes to tumor incidence.
- Occupational or environmental high-risk groups, such as those with long-term exposure to carcinogens or radiation [12-14,61].

For these groups, hTERT vaccination could complement existing surveillance programs, serving as an immunological firewall against cancer initiation [12-14,61].

Preclinical Evidence Supporting Immunopreventive Efficacy

Animal models have provided preliminary validation of telomerase-targeted immunoprevention. In murine systems engineered to express human telomerase, peptide vaccination with hTERT epitopes induced robust

T-cell immunity and delayed or completely prevented tumor formation in carcinogen-induced and spontaneous tumor models. Importantly, these studies reported no evidence of autoimmune pathology or impaired regenerative function in high-turnover tissues such as bone marrow or intestinal mucosa [27,62].

These findings imply that immune recognition of telomerase can selectively target pre-malignant or dysplastic cells while sparing healthy progenitors, supporting the safety and feasibility of preventive application in humans [27,62].

Ethical, Regulatory, and Logistical Considerations

Implementing a cancer-preventive vaccine based on hTERT will necessitate careful ethical and regulatory oversight. Administering a vaccine against a self-antigen to healthy individuals raises concerns regarding autoimmunity, informed consent, and long-term follow-up. In addition, measuring vaccine efficacy in prevention requires novel endpoints, such as reduction in precancerous lesions or molecular biomarkers (e.g., circulating hTERT mRNA, telomerase activity assays), rather than classical tumor regression [13-14,63].

From a logistical standpoint, low-cost, stable vaccine formulations, such as peptide or DNA-based constructs, are preferable for large-scale public health deployment. Advances in bioinformatics epitope prediction, synthetic vaccine manufacturing, and nanoparticle delivery can further enhance the accessibility of such immunopreventive interventions in low- and middle-income regions [13-14,63].

Integration with Early Detection and Precision Medicine

The success of hTERT immunoprevention will depend on integration with precision oncology tools that identify at-risk individuals. Biomarkers such as circulating telomerase reverse transcriptase mRNA, telomeric DNA content, or hTERT promoter mutations can serve as early indicators of field cancerization, guiding vaccination decisions. In the future, multi-omics data combined with AI-based risk modeling may enable personalized vaccination schedules, optimizing timing and dosing to sustain long-term immune vigilance [10-12,64].

Summary

The extension of hTERT vaccination into the realm of cancer prevention represents a paradigm shift, from reactive treatment to proactive immune defense. By harnessing immunological memory against a universal and early tumor antigen, such vaccines could prevent the onset of multiple cancers simultaneously. The scientific, ethical, and logistical groundwork established in therapeutic trials now paves the way for translational research focused on preventive implementation [62-64].

Table 2: Potential Preventive Applications and High-Risk Target Populations for hTERT Vaccination [12-14,63]

Risk Category	Representative Conditions or Settings	Preventive Rationale	Potential Benefit
Genetic predisposition	BRCA1/2 mutation carriers, Li-Fraumeni syndrome (TP53), Lynch syndrome (MLH1/MSH2)	Early activation of telomerase in pre-neoplastic clones	Delay or prevention of hereditary cancer onset
Chronic inflammation / infection	Chronic hepatitis B/C, ulcerative colitis, Barrett's esophagus, HPV-negative cervical dysplasia	Persistent regenerative stress increases telomerase activation	Interception of inflammation-driven carcinogenesis
Premalignant lesions	Colonic adenomas, oral leukoplakia, cervical intraepithelial neoplasia	High telomerase activity detected in dysplastic tissue	Regression or stabilization of precancerous changes
Environmental or occupational risk	Long-term exposure to carcinogens, radiation, or industrial pollutants	Cumulative DNA damage and clonal expansion	Reduced incidence of induced malignancies
Age-related risk / immunosenescence	Individuals >60 years, decreased immune surveillance	Rising telomerase reactivation with age	Restoration of immune monitoring, delayed cancer onset

Table 2 outlines the principal target populations and clinical contexts in which hTERT-based vaccination could serve as a preventive or early-intervention strategy. These groups represent individuals with heightened risk of telomerase reactivation due to genetic predisposition, chronic inflammation, environmental exposure, or age-related immune decline. By establishing long-lasting immune memory against hTERT-expressing cells, vaccination in these populations could intercept early oncogenic events, delay malignant transformation, and ultimately reduce cancer incidence. The classification presented in this table provides a conceptual roadmap for future translational studies aiming to integrate telomerase immunoprevention into precision medicine and population-level cancer control programs [12-14,63].

Advances in Peptide and Multi-Epitope Vaccine Design Targeting hTERT

Progress in computational biology and molecular immunology has transformed vaccine development from empirical experimentation into a data-driven design process. In the case of hTERT-based vaccines, the ability to predict, engineer, and model antigenic epitopes *in silico* has enabled the rational design of constructs that elicit broad, durable, and safe immune responses. These innovations are critical for the transition from therapeutic to preventive vaccination, where efficacy, safety, and scalability must coexist [13,64].

Computational Prediction of hTERT Epitopes

Modern immunoinformatics tools, such as IEDB, NetMHCpan, VaxiJen, TepiTool, and AllerTOP, allow precise identification of peptide segments within hTERT that bind multiple HLA alleles with high affinity.

- CD8⁺ CTL epitopes (typically 8–11 aa) are screened for MHC class I binding, proteasomal cleavage probability, and TAP transport efficiency.
- CD4⁺ helper T-cell epitopes (12–25 aa) are predicted for MHC class II binding and IFN- γ induction potential.
- Predicted epitopes are further filtered for antigenicity, non-allergenicity, non-toxicity, and sequence conservation across tumor types.

Using this pipeline, multiple immunogenic hotspots within the hTERT reverse transcriptase and C-terminal domains have been identified, forming the foundation for multi-epitope vaccine design [30,64,65].

Multi-Epitope Vaccine Construction

Unlike early single-peptide vaccines such as GV1001, next-generation designs combine multiple CTL and helper epitopes into a single chimeric construct capable of stimulating a balanced Th1-biased immune response [15-17].

Key Design Principles Include:

- Linkers (e.g., AAY, GPMPG) to preserve epitope independence and facilitate proteasomal processing.
- Universal helper epitopes such as PADRE to enhance MHC class II coverage across populations.
- Adjuvant peptides (e.g., human β -defensin 2, flagellin fragments, or TLR ligands) at the N-terminus to boost innate activation.
- Flexible peptide length (100–300 aa) allowing inclusion of multiple conserved epitopes from different hTERT domains.

This combinatorial approach increases HLA coverage, reduces immune escape, and supports applicability across genetically diverse populations, crucial for a universal cancer vaccine [15-17,63].

Structural Modeling and Molecular Docking

Three-dimensional structural modeling validates the predicted interaction between hTERT epitopes and HLA molecules. Tools such as PEP-FOLD, DockThor, and ClusPro simulate peptide–HLA binding conformations, while Molecular Dynamics (MD) simulations assess binding stability. High-affinity binding ($\Delta G < -6$ kcal/mol) indicates effective presentation potential. Visualization of these complexes informs refinement of peptide sequences to optimize MHC contact residues, ensuring strong and stable immunogenic presentation [64-66].

In Silico Immune Simulation

The predicted immunological performance of a multi-epitope construct can be evaluated using C-ImmSim, an agent-based immune simulator that models cytokine dynamics, T-cell proliferation, antibody titers, and memory formation. Such simulations have shown that hTERT multi-epitope vaccines can induce robust IFN- γ and IL-2 responses with sustained memory up to 350 days post-vaccination, outcomes consistent with long-term cancer surveillance. These analyses reduce experimental cost and accelerate optimization before laboratory validation [24-25,64].

Adjuvant Engineering and Delivery Platforms

Effective hTERT vaccination depends on delivering peptide antigens in an immunostimulatory context. Several complementary innovations are under investigation:

- Nanoparticle carriers (liposomes, PLGA microspheres, gold nanoparticles) that enhance antigen stability and dendritic-cell uptake.
- Self-assembling peptide scaffolds that present epitopes in repetitive arrays mimicking viral capsids.
- DNA and mRNA expression systems encoding multi-epitope sequences for in vivo antigen synthesis.
- Dendritic-cell (DC)–based ex vivo loading, where patient DCs are pulsed with hTERT peptides before reinfusion, bridging peptide vaccination and personalized immunotherapy.
- Together, these delivery systems enable precise antigen targeting while minimizing systemic reactivity [12-14,67].

Integration of Artificial Intelligence in Vaccine Optimization

Machine-learning algorithms are increasingly employed to predict antigen–HLA binding affinities, optimize codon usage, and identify novel immunogenic motifs. AI-driven network analyses can integrate transcriptomic and proteomic datasets to reveal cancer-specific neoantigens overlapping with hTERT-related pathways,

guiding personalized vaccine refinement. Such computational frameworks accelerate the transition from concept to candidate formulation with unprecedented speed and accuracy [13,68].

Conceptual Overview

Figure 2 illustrates the conceptual framework of a multi-epitope hTERT-based universal cancer vaccine. The schematic will depict the stepwise process from computational epitope prediction and structural modeling to vaccine assembly, adjuvant selection, and immune activation. It will highlight how integrated CD4⁺ and CD8⁺ responses converge to eliminate hTERT-expressing precancerous or malignant cells, representing the immunological foundation of universal cancer prevention [14,43].

Advances in bioinformatics and molecular design have enabled the rational development of multi-epitope vaccines targeting conserved regions of telomerase reverse transcriptase (hTERT). Figure 2 summarizes the conceptual workflow underlying this next-generation approach, from computational epitope discovery and structural modeling to construct assembly, delivery optimization, and immune activation. The figure illustrates how integrating both CD4⁺ and CD8⁺ T-cell epitopes, supported by adjuvants and innovative delivery platforms, can establish a coordinated immune response capable of recognizing and eliminating hTERT-expressing precancerous or malignant cells [43-45,64].




Figure 2: Conceptual Design of a Multi-Epitope hTERT-Based Universal Cancer Vaccine [43-45,64]

The schematic illustrates the rational design workflow for developing a universal multi-epitope hTERT vaccine. Computational tools identify conserved cytotoxic (CD8⁺) and helper (CD4⁺) T-cell epitopes from hTERT, which are linked with appropriate spacers and adjuvant peptides to form a chimeric construct. Structural modeling and molecular docking validate peptide-MHC interactions, followed by delivery optimization using nanoparticles, DNA/mRNA vectors, or dendritic-cell platforms. Upon administration, the vaccine induces coordinated innate and adaptive immune activation, leading to long-term memory formation and targeted elimination of hTERT-expressing cells [43-45,64].

Future Prospects

The convergence of computational immunology, peptide engineering, and nanotechnology now enables the rational design of preventive cancer vaccines once deemed unattainable. For hTERT, these advances open the possibility of population-level prophylactic vaccination analogous to infectious-disease immunization. Moving forward, integrating in silico epitope discovery with in vitro validation and in vivo safety assessment will be critical for translating these designs into clinical reality [11,64].

Synergistic Strategies: Combining hTERT Vaccines with Modern Immunotherapies

While hTERT-based vaccines can elicit antigen-specific T-cell responses, their efficacy may be limited in established tumors by immune suppression within the tumor microenvironment. Combining telomerase

vaccination with modern immunotherapies provides a powerful strategy to overcome these barriers, enhance effector-cell function, and achieve durable tumor control or prevention. This integrative approach represents the next evolutionary step in telomerase immunology, linking antigen-specific priming with systemic immune modulation [50,69].

Rationale for Combination Strategies

The tumor immune microenvironment (TIME) is often characterized by chronic inflammation, regulatory T-cell infiltration, and expression of inhibitory checkpoints such as PD-1, CTLA-4, and LAG-3, which suppress T-cell activation. hTERT-based vaccination alone may induce specific cytotoxic responses, but these effector cells can become exhausted or anergic upon encountering immunosuppressive signals within tumors. Therefore, combining vaccination with checkpoint blockade or other immunomodulators can amplify and sustain anti-tumor immunity, transforming otherwise transient immune responses into durable therapeutic or preventive protection [49,70].

Checkpoint Inhibitors as Potentiators of hTERT Vaccines

Checkpoint inhibitors targeting PD-1/PD-L1 or CTLA-4 pathways reinvigorate exhausted T cells and enhance tumor antigen recognition. Clinical data from UV1 combination trials have demonstrated that co-administration of telomerase vaccines with nivolumab or pembrolizumab significantly increases immune activation and overall survival compared to checkpoint blockade alone. This synergy arises from complementary mechanisms: the vaccine expands hTERT-specific T-cell clones, while checkpoint inhibition sustains their effector function by relieving tumor-induced suppression [17,43].

Future studies may explore triple-combination regimens, pairing hTERT vaccination with dual checkpoint inhibitors (e.g., PD-1 and LAG-3 blockade) to achieve maximal immune reactivation across diverse tumor types [13,71].

Integration with Cytokine and Costimulatory Pathway Modulation

Cytokine-based immunotherapy provides another means of boosting vaccine-induced responses.

Agents such as interleukin-2 (IL-2), GM-CSF, or IL-15 can enhance T-cell proliferation and antigen presentation. In particular, GM-CSF serves a dual role as a vaccine adjuvant, recruiting and activating dendritic cells at the injection site, an approach already incorporated into UV1 formulations [41,72]. Emerging strategies also include agonists of costimulatory receptors (e.g., OX40, 4-1BB, CD27) that further potentiate the expansion and survival of vaccine-induced effector T cells. The judicious use of these cytokines and costimulatory modulators can enhance both the amplitude and longevity of telomerase-specific immunity [41,72].

Oncolytic Viruses and Tumor Microenvironment Reprogramming

Oncolytic viruses, engineered to selectively replicate within tumor cells, can transform “cold” tumors into “hot” immunogenic environments. When combined with hTERT-based vaccines, viral oncolysis releases tumor-associated antigens, increases local inflammation, and facilitates cross-presentation of telomerase-derived peptides by dendritic cells [33,73].

Preclinical studies using MVA-hTERT (Modified Vaccinia Ankara vector expressing hTERT) have demonstrated potent T-cell priming and immune infiltration, supporting this synergistic concept. Additionally, metabolic or epigenetic reprogramming of the tumor microenvironment, through inhibitors of IDO1, TGF- β , or VEGF, can further enhance the efficacy of hTERT-targeted immunization by restoring antigen presentation and T-cell trafficking [33,73].

Combination with Adoptive and Cellular Immunotherapies

Adoptive cell transfer (ACT) strategies, including TCR-engineered T cells or CAR-T cells targeting hTERT epitopes, represent another dimension of synergy. Vaccination can serve as an *in vivo* boost to maintain the persistence and functionality of infused hTERT-specific T-cell populations. Conversely, ACT provides an immediate source of potent effector cells that complement the slower kinetics of vaccine-induced immunity. Together, these approaches could establish both rapid and sustained immune surveillance against telomerase-expressing cancers [36,74].

Timing and Sequence Optimization

The sequence of administration plays a crucial role in maximizing synergy. In therapeutic contexts, checkpoint inhibition typically precedes or overlaps with vaccination, ensuring that newly generated hTERT-specific T cells encounter a permissive immune milieu. In preventive scenarios, vaccination could precede checkpoint exposure, establishing immunological memory before potential tumor development. Such temporal optimization will be essential to balance efficacy with safety, particularly in long-term immunopreventive settings [17,75].

Advantages and Challenges of Combination Strategies

Advantages of combination regimens include enhanced T-cell activation, broader epitope recognition, mitigation of immune escape, and potential elimination of minimal residual disease. However, challenges remain, including the risk of immune-related adverse events (irAEs), complex dosing regimens, and increased cost. Identifying biomarkers, such as circulating hTERT-specific T-cell frequencies, cytokine signatures, or PD-L1 expression levels, may enable stratification of patients most likely to benefit from combination immunotherapy [13,48].

Outlook

The combination of hTERT vaccination with modern immunotherapies represents a powerful convergence of antigen specificity and immune modulation. By integrating telomerase-targeted priming with checkpoint blockade, cytokine therapy, and cellular immunotherapy, it is now possible to orchestrate multi-layered immune responses capable of both eliminating existing tumors and preventing recurrence. For future clinical development, these synergistic strategies will likely define the blueprint for telomerase-centered combination immunoprevention, merging precision antigen design with holistic immune system activation [12-14].

Challenges, Limitations, and Unresolved Questions

Despite remarkable progress in telomerase-based vaccine research, several scientific, clinical, and logistical challenges remain before hTERT immunization can be adopted as a universal preventive strategy. These limitations span across immunobiology,

translational feasibility, safety, and ethical considerations, underscoring the complexity of targeting a self-derived antigen for population-level cancer prevention [13,56].

Variability in Epitope Presentation and HLA Restriction

A key biological challenge lies in the diversity of HLA alleles across human populations, which influences antigen processing and presentation. While multi-epitope vaccine designs aim to broaden coverage, interindividual variability in HLA binding affinity may result in heterogeneous immune responses. Moreover, tumors can downregulate MHC class I expression or alter proteasomal processing, leading to immune escape despite effective vaccination. Addressing this requires ongoing refinement of epitope prediction algorithms, inclusion of pan-HLA binding epitopes, and potential use of personalized neoepitope libraries to ensure consistent efficacy across ethnic and genetic backgrounds [36,76].

Immune Tolerance and Regulatory Mechanisms

Because hTERT is a self-protein, central and peripheral immune tolerance remain significant barriers. Many telomerase-specific T cells possess low affinity due to negative thymic selection, limiting the amplitude of vaccine-induced responses. Furthermore, regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment can suppress telomerase-reactive effector cells. Overcoming tolerance safely will require balancing immune activation with controlled modulation of regulatory pathways, potentially through combination with checkpoint inhibitors or selective Treg depletion [50-52].

Duration of Immune Memory and Booster Requirements

While early studies show that hTERT-specific T-cell memory can persist for years, the optimal duration and frequency of booster immunization remain unknown, particularly for preventive use in healthy individuals. The long latency of many cancers poses an additional challenge, preventive immunity must be both durable and safely maintainable over decades. Defining correlates of protection (e.g., IFN- γ -producing CD8⁺ T-cell levels) and longitudinally tracking vaccine-induced immunity will be essential for establishing evidence-based booster regimens [50-52].

Autoimmune and Safety Considerations

Although clinical data thus far demonstrate favorable safety profiles, potential autoimmune toxicity cannot be fully excluded in large-scale preventive applications. Low-level telomerase activity exists in stem cells, germ cells, and activated lymphocytes, raising theoretical concerns of off-target cytotoxicity. Chronic inflammation triggered by sustained immune activation could also accelerate tissue aging or fibrosis. Therefore, extended safety surveillance and comprehensive preclinical toxicology are mandatory before deploying hTERT vaccines in non-cancer populations [50-52].

Manufacturing, Cost, and Accessibility

Transitioning from personalized or small-scale therapeutic trials to mass immunization programs presents major logistical challenges. Peptide synthesis, adjuvant formulation, and cold-chain distribution all affect scalability and cost. To ensure equitable access, vaccine platforms must be thermostable, inexpensive, and compatible with low-resource settings. DNA or mRNA vaccine technologies offer potential solutions, but require continued optimization for consistent expression and immune potency. Global partnerships will be critical to translating laboratory success into public health impact [53-55].

Clinical Trial Design and Regulatory Pathways

Designing clinical trials for cancer prevention differs fundamentally from therapeutic oncology. Measuring endpoints such as reduction in cancer incidence, delay in onset, or molecular biomarker modulation requires long-term follow-up and large cohort sizes. Regulatory frameworks currently tailored for infectious disease vaccines must evolve to accommodate immunopreventive agents targeting self-antigens. Adaptive trial designs, combined with biomarker-based surrogate endpoints (e.g., hTERT mRNA or circulating telomerase activity), may accelerate approval while maintaining safety rigor [36-38].

Ethical and Social Implications

Vaccinating healthy individuals against a disease that may or may not develop introduces unique ethical challenges. Issues of informed consent, risk-benefit assessment, and psychological impact must be carefully addressed. Public perception of “anti-cancer vaccination” could oscillate between optimism and

apprehension, necessitating transparent communication and public education. Moreover, disparities in healthcare access could amplify global inequities unless hTERT vaccines are integrated into inclusive preventive health frameworks [9,63].

Unresolved Scientific Questions

Several key questions remain unanswered:

- Can immune memory against a single antigen like hTERT truly provide cross-cancer protection over decades?
- What are the molecular signatures of effective immunoprevention, and how can they be monitored noninvasively?
- Could telomerase inhibition or immune pressure drive tumor evolution toward telomerase-independent mechanisms?
- To what extent does the microbiome or host metabolism modulate telomerase-specific immunity?

Addressing these questions will require interdisciplinary collaboration between immunologists, oncologists, systems biologists, and bioinformaticians, leveraging longitudinal human cohorts and advanced computational modelling [4,5].

Summary

In summary, while hTERT-based vaccination holds immense promise as a foundation for universal cancer immunoprevention, several biological and translational barriers must still be resolved. Overcoming immune tolerance, ensuring durable safety, and developing cost-effective large-scale platforms remain the critical steps toward realizing this vision. Continued innovation in computational design, immunomodulatory combinations, and ethical frameworks will determine whether telomerase immunization can transition from experimental concept to a cornerstone of global cancer prevention [13,50].

Future Perspectives: Roadmap Toward a Universal Cancer Vaccine

The vision of a universal cancer vaccine, one capable of providing long-term immune protection against multiple malignancies, represents a transformative goal at the intersection of immunology, oncology, and computational biology. While still aspirational, recent advances in telomerase biology, immunoinformatics, and vaccine engineering have brought this concept within reach. To translate hTERT-based

immunoprevention from experimental innovation to global clinical reality, a structured roadmap encompassing scientific, technological, and societal dimensions is essential [11,64].

Integration of Artificial Intelligence and Systems Immunology

The application of artificial intelligence (AI) and systems immunology can revolutionize the process of vaccine discovery. Machine-learning algorithms trained on multi-omics datasets, encompassing genomics, transcriptomics, and proteomics, can predict immunogenic epitopes with unprecedented precision and model complex host–tumor interactions. AI-guided network analyses could also identify synergistic antigen combinations that augment hTERT's immunogenic potential, enabling the creation of optimized multi-antigen preventive vaccines. These computational approaches reduce experimental burden, shorten development timelines, and promote population-level adaptability [9,68].

Personalized Immunoprevention for Hereditary Cancer Syndromes

While the long-term vision is population-wide immunization, early deployment may focus on genetically predisposed individuals, for instance, carriers of BRCA1/2, TP53, or APC mutations. Integrating hTERT vaccination with genetic counseling and early surveillance could create a new tier of precision prevention. Personalized hTERT-based vaccine constructs, adjusted for each patient's HLA profile and mutational background, could provide individualized immune fortification against high-likelihood tumorigenesis. Such precision immunoprevention would pioneer a proactive, genotype-driven strategy in oncology [37,55].

Biomarker-Integrated Surveillance Programs

The success of cancer immunoprevention will depend on the ability to detect and monitor early oncogenic activation. Biomarkers such as circulating hTERT mRNA, telomerase activity assays, or cell-free tumor DNA (cfDNA) can serve as measurable correlates of early transformation and vaccine efficacy. Combining vaccination with regular biomarker surveillance could create dynamic prevention programs that adapt booster schedules based on immune response durability and risk fluctuation, mirroring

models already used in infectious disease immunology [10,77].

Harnessing the Microbiome and Metabolic Modulation

Emerging evidence links the gut microbiome to immune responsiveness and cancer susceptibility. Commensal microbes modulate T-cell priming, cytokine production, and systemic inflammation, influencing vaccine outcomes. Future studies may explore microbiome engineering or metabolic reprogramming (via diet, probiotics, or metabolites) to enhance telomerase-specific immune memory. Such integrative strategies align cancer immunoprevention with the broader paradigm of systems health, emphasizing equilibrium between host immunity, metabolism, and microbial ecology [50,78].

Development of Low-Cost, Scalable Vaccine Platforms

For hTERT vaccination to achieve global impact, it must be affordable, stable, and widely distributable. Advances in DNA, mRNA, and peptide nanovaccine technologies now allow production without cold-chain dependency and at substantially reduced cost. Modular vaccine platforms can be easily adapted for new antigens or population-specific epitope sets, facilitating rapid deployment in diverse healthcare settings. Partnerships between academic institutions, biotech industries, and public health agencies will be pivotal to ensure equitable access, especially in low- and middle-income countries [12-14].

Longitudinal Clinical Trials and Global Collaboration

The preventive nature of telomerase vaccination necessitates long-term, multicentric clinical trials integrating molecular, immunological, and epidemiological endpoints. International collaboration will be key to achieving sufficient statistical power and diversity in HLA representation. Establishing global consortia for cancer immunoprevention research, analogous to existing infectious disease vaccine networks, can accelerate data sharing, standardize immune monitoring assays, and harmonize regulatory pathways. Such efforts will transform hTERT vaccination from an isolated research frontier into a coordinated international initiative [11,76].

Ethical and Policy Considerations in Population-Level Prevention

The eventual introduction of a universal cancer vaccine will require ethical frameworks balancing individual autonomy with collective benefit. Policymakers must address issues related to consent, surveillance, and prioritization of at-risk groups. Transparent communication regarding vaccine safety, scientific rationale, and realistic expectations will be crucial to maintain public trust. Integration into national cancer control programs, alongside screening, early detection, and lifestyle modification, will help maximize societal impact while minimizing ethical tension [9,79].

The Long-Term Vision: Cancer as a Preventable Disease

In the long term, telomerase-based immunization could redefine cancer from an unpredictable, treatment-dependent disease to a largely preventable biological event. As immunological literacy advances and preventive vaccination becomes integrated into routine healthcare, the concept of “cancer-free generations” may transition from aspiration to attainable reality. The development of a universal cancer vaccine anchored on hTERT represents not only a scientific milestone but also a paradigm shift in human health, transforming oncology from curative medicine into proactive immunological protection [8,13].

Conclusion

The development of telomerase reverse transcriptase (hTERT)–based vaccines represents one of the most promising frontiers in modern oncology. By targeting a molecular hallmark shared by the majority of human cancers, these vaccines transcend tumor-type specificity, offering a unifying strategy for both therapeutic and preventive applications. Over two decades of research, from early peptide formulations such as GV1001 to next-generation platforms like UV1, have established the feasibility, safety, and immunogenicity of telomerase-directed immunization [15-17].

However, the transition from treatment to prevention marks a new scientific paradigm: cancer as an immunologically preventable disease. Achieving this goal will require continued innovation in epitope design, adjuvant engineering, and delivery systems, combined with synergy from checkpoint inhibitors,

cytokine modulators, and cellular therapies. Equally vital will be the integration of AI-guided bioinformatics, biomarker-based surveillance, and global collaboration to refine predictive models, ensure equitable access, and maintain ethical rigor [42,64].

Ultimately, hTERT embodies the ideal antigenic foundation for a universal cancer vaccine, a concept once aspirational, now biologically plausible. The future of oncology may thus evolve beyond cure toward immune prevention, transforming cancer from a terminal diagnosis into a largely avoidable biological event. Continued interdisciplinary commitment between immunologists, molecular biologists, clinicians, and computational scientists will determine how swiftly this vision transitions from theory to tangible global health reality [9-11].

References

1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, et al. (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 74: 229-263.
2. Seong H, Izutsu R, Osaki M, Okada F (2025) Cancer prevention: past challenges and future directions. *Genes Environ* 47: 4.
3. Marino P, Mininni M, Deiana G, Marino G, Divella R, et al. (2024) Healthy lifestyle and cancer risk: modifiable risk factors to prevent cancer. *Nutrients* 16: 800.
4. Zhou Y, Wei Y, Tian X, Wei X (2025) Cancer vaccines: current status and future directions. *J Hematol Oncol* 18: 18.
5. Lei W, Zhou K, Lei Y, Li Q, Zhu H (2025) Cancer vaccines: platforms and current progress. *Mol Biomed* 6: 3.
6. Flores JE, Thompson AJ, Ryan M, Howell J (2022) The global impact of hepatitis B vaccination on hepatocellular carcinoma. *Vaccines* 10: 793.
7. Avila-Aguero ML, Ospina-Henao S, Brenes-Chacon H, Espinal-Tejada C, Trejo-Varon R, et al. (2025) Human papilloma virus vaccination as a strategy to eliminate cervical cancer: challenges and opportunities. *Vaccines* 13: 297.
8. Ruzzi F, Riccardo F, Conti L, Tarone L, Semprini MS, et al. (2024) Cancer vaccines: target antigens, vaccine platforms and preclinical models. *Mol Aspects Med* 101: 101324.

9. Liu J, Fu M, Wang M, Wan D, Wei Y, et al. (2022) Cancer vaccines as promising immuno-therapeutics: platforms and current progress. *J Hematol Oncol* 15: 28.
10. Palamarchuk AI, Kovalenko EI, Streltsova MA (2023) Multiple actions of telomerase reverse transcriptase in cell death regulation. *Biomedicines* 11: 1091.
11. Yuan X, Xu D (2019) Telomerase reverse transcriptase (TERT) in action: cross-talking with epigenetics. *Int J Mol Sci* 20: 3338.
12. Liu M, Zhang Y, Jian Y, Gu L, Zhang D, et al. (2024) The regulations of telomerase reverse transcriptase (TERT) in cancer. *Cell Death Dis* 15: 90.
13. Vahidi S, Zabeti Touchaei A (2024) Telomerase-based vaccines: a promising frontier in cancer immunotherapy. *Cancer Cell Int* 24: 421.
14. Ibrahim EIK, Ellingsen EB, Mangsbo SM, Friberg LE (2024) Bridging responses to a human telomerase reverse transcriptase-based peptide cancer vaccine candidate in a mechanism-based model. *Int Immunopharmacol* 126: 111225.
15. Bernhardt SL, Gjertsen MK, Trachsel S, Møller M, Eriksen JA, et al. (2006) Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose-escalating phase I/II study. *Br J Cancer* 95: 1474-1482.
16. Fenoglio D, Traverso P, Parodi A, Kalli F, Zanetti M, et al. (2013) Generation of more effective cancer vaccines. *Hum Vaccin Immunother* 9: 2543-2547.
17. Ellingsen EB, Mangsbo SM, Hovig E, Gaudernack G (2021) Telomerase as a target for therapeutic cancer vaccines and considerations for optimizing their clinical potential. *Front Immunol* 12: 682492.
18. Boccardi V, Marano L (2024) Aging, cancer, and inflammation: the telomerase connection. *Int J Mol Sci* 25: 8542.
19. Leão R, Apolónio JD, Lee D, Figueiredo A, Tabori U, et al. (2018) Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer. *J Biomed Sci* 25: 22.
20. Agrawal S, Lin X, Susvirkar V, O'Connor MS, Chavez BL, et al. (2025) Human RPA is an essential telomerase processivity factor for maintaining telomeres. *Science* 390: 495-502.
21. Ramlee M K, Wang J, Toh W X, Li S (2016) Transcription regulation of the human telomerase reverse transcriptase (hTERT) gene. *Genes* 7: 50.
22. Santourlidis S, Juan Albasanz MJ, Buroh RT, Hoffmann M, Bendhack ML, et al. (2024) hTERT epigenetics provides new perspectives for diagnosis and evidence-based guidance of chemotherapy in cancer. *Int J Mol Sci* 25: 7331.
23. Shitova M, Alpeeva E, Vorotelyak E (2024) Review of hTERT-immortalized cells: how to assess immortality and confirm identity. *Int J Mol Sci* 25: 13054.
24. Chen R, Li G, Dakic A, Zheng Y-L, Li J, et al. (2025) The hTERT N-terminal DNA binding is necessary but not sufficient for maintaining telomere and cellular immortalization. *Serican J Med* 2.
25. Carlund O, Norberg A, Osterman P, Andersson I, Eriksson A, et al. (2025) Telomerase activity in T-cells as a functional test for pathogenicity assessment of novel genetic variants in telomere biology disorders. *Sci Rep* 15:29048.
26. Wang K, Wang R-L, Liu J-J, Zhou J, Li X, et al. (2018) The prognostic significance of hTERT overexpression in cancers: a systematic review and meta-analysis. *Medicine (Baltimore)* 97: e11794.
27. Mizukoshi E, Kaneko S (2019) Telomerase-targeted cancer immunotherapy. *Int J Mol Sci* 20: 1823.
28. Philips AV, Kerros C, Hong H, Shi C, Allen J, et al. (2024) Targeting NRP1 on tumors with an exogenous antigen-linked anti-NRP1 antibody results in antigen cross-presentation and tumor killing by memory T cells. *J Immunother Cancer* 12: A1175.
29. Rotem O, Zer A, Yosef L, Beery E, Goldvaser H, et al. (2023) Blood-derived exosomal hTERT mRNA in patients with lung cancer: characterization and correlation with response to therapy. *Biomedicines* 11: 1730.
30. Liu H, Liu Q, Ge Y, Zhao Q, Zheng X, et al. (2016) hTERT promotes cell adhesion and migration independent of telomerase activity. *Sci Rep* 6: 22886.
31. Patrick M, Weng NP (2019) Expression and regulation of telomerase in human T cell differentiation, activation, aging and diseases. *Cell Immunol* 345: 103989.
32. Zhao C, Jia B, Jiang Y, Shike H, Annageldiyev C, et al. (2025) Cytotoxic lymphocytes induced by engineered human dendritic cells mediate potent anti-leukemia activity. *Cancer Immunol Immunother* 74: 117

33. Jin M, Huang J-D (2023) New mechanism to promote long-term T-cell immunity by telomere transfer from antigen-presenting cells. *Cell Mol Immunol* 20: 117-118.
34. Dillard P, Köksal H, Maggadottir SM, Winge-Main A, Pollmann S, et al. (2021) Targeting telomerase with an HLA class II-restricted TCR for cancer immunotherapy. *Mol Ther* 29: 1199-1211.
35. Wang C, Gu H, Cai J, Zhu C, Zheng Q, et al. (2025) Enhanced detection of circulating tumor cells using a MUC1 promoter-driven recombinant adenovirus. *Front Oncol* 14: 1506968.
36. Vahidi S, Zabeti Touchaei A (2024) Telomerase-based vaccines: a promising frontier in cancer immunotherapy. *Cancer Cell Int* 24: 421.
37. Wang Y, Zhang X, Chen G, Shao M (2024) Clinical research progress of telomerase-targeted cancer immunotherapy: a literature review. *Transl Cancer Res* 13: 3904-3921.
38. Murillo-Ortiz BO, García-Corrales K, Martínez-Garza S, Romero-Vázquez MJ, Agustín-Godínez E, et al. (2024) Association of hTERT expression, Her2Neu, estrogen receptors, progesterone receptors, with telomere length before and at the end of treatment in breast cancer patients. *Front Med* 11: 1450147.
39. Đukić A, Lulić L, Thomas M, Skelin J, Bennett Saidu NE, et al. (2020) HPV oncoproteins and the ubiquitin proteasome system: a signature of malignancy? *Pathogens* 9: 133.
40. Duraiswamy J, Turrini R, Minasyan A, Barras D, Crespo I, et al. (2021) Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. *Cancer Cell* 39: 1623-1642.
41. Huang L, Zhang M, Bai D, Qu Y (2024) Deciphering the impact of TERT/telomerase on immunosenescence and T cell revitalization. *Front Immunol* 15: 1465006.
42. Stanton SE, Castle PE, Finn OJ, Sei S, Emens LA (2024) Advances and challenges in cancer immunoprevention and immune interception. *J Immunother Cancer* 12: e007815.
43. Xie L, Fang J, Yu J, Zhang W, He Z, et al. (2023) The role of CD4⁺ T cells in tumor and chronic viral immune responses. *Med Comm* 4: e390.
44. Graydon EK, Conner TL, Dunham K, Olsen C, Goguet E, et al. (2023) Natural killer cells and BNT162b2 mRNA vaccine reactogenicity and durability. *Front Immunol* 14: 1225025.
45. Jeon D, Hill E, McNeel DG (2024) Toll-like receptor agonists as cancer vaccine adjuvants. *Hum Vaccin Immunother* 20: 2297453.
46. Yik MY, Azlan A, Rajasegaran Y, Rosli A, Yusoff NM, et al. (2021) Mechanism of human telomerase reverse transcriptase (hTERT) regulation and clinical impacts in leukemia. *Genes* 12: 1188.
47. Romaniuk-Drapała A, Totoń E, Konieczna N, Machnik M, Barczak W, et al. (2021) hTERT down-regulation attenuates resistance to DOX, impairs FAK-mediated adhesion, and leads to autophagy induction in breast cancer cells. *Cells* 10: 867.
48. Buchbinder EI, Desai A (2016) CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. *Am J Clin Oncol* 39: 98-106.
49. Jiang Y, Zhou Y, Wang Y, Li Z, Ashraf GM, et al. (2025) Telomerase dynamics in stem cells: unraveling the molecular nexus of cellular aging and regeneration. *Ageing Res Rev* 112: 102853.
50. Leão R, Apolónio JD, Lee D, Figueiredo A, Tabori U, et al. (2018) Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer. *J Biomed Sci* 25: 22.
51. Patrick M, Cheng N-L, Kim J, An J, Dong F, et al. (2019) Human T cell differentiation negatively regulates telomerase expression resulting in reduced activation-induced proliferation and survival. *Front Immunol* 10: 1993.
52. Germain C, Garibal J, Doppler V, Baran-Marszak F, Cymbalista F, et al. (2021) Anti-telomerase immune response predicts disease progression in chronic lymphocytic leukemia. *Clin Immunol Commun* 1: 35-44.
53. Pagliari S, Dema B, Sanchez-Martinez A, Montalvo Zurbia-F G, Rollier CS (2023) DNA vaccines: history, molecular mechanisms and future perspectives. *J Mol Biol* 435: 168297.
54. Zhang G, Tang T, Chen Y, Huang X, Liang T (2023) mRNA vaccines in disease prevention and treatment. *Signal Transduct Target Ther* 8: 365.
55. Secli L, Leoni G, Ruzza V, Siani L, Cotugno G, et al. (2023) Personalized cancer vaccines go viral: viral vectors in the era of personalized immunotherapy of cancer. *Int J Mol Sci* 24: 16591.
56. Aamdal E, Inderberg EM, Ellingsen EB, Rasch W, Brunsvig PF, et al. (2021) Combining a universal telomerase-based cancer vaccine with ipilimumab in patients with metastatic melanoma—five-year

- follow-up of a phase I/IIa trial. *Front Immunol* 12: 663865.
57. Chen Z, Vallega KA, Wang D, Quan Z, Fan S, et al. (2024) Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR-mutant lung cancer. *J Exp Med* 221: e20240435.
 58. Vraga EK, Brady SS, Gansen C, Khan EM, Bennis SL, et al. (2023) A review of HPV and HBV vaccine hesitancy, intention, and uptake in the era of social media and COVID-19. *eLife* 12: e85743.
 59. Hannen R, Bartsch JW (2018) Essential roles of telomerase reverse transcriptase hTERT in cancer stemness and metastasis. *FEBS Lett* 592: 2023-2031.
 60. Di Bartolomeo L, Vaccaro F, Irrera N, Borgia F, Li Pomi F, et al. (2023) Wnt signaling pathways: from inflammation to non-melanoma skin cancers. *Int J Mol Sci* 24: 1575.
 61. Negrini S, De Palma R, Filaci G (2020) Anti-Cancer immunotherapies targeting telomerase. *Cancers* 12: 2260.
 62. Attar A, Khosravi Maharlooee M, Nazarinia MA, Hosseini A, Bajalli Z, et al. (2020) Expression pattern of telomerase reverse transcriptase (hTERT) variants and Bcl-2 in peripheral lymphocytes of systemic lupus erythematosus patients. *Iran J Pathol* 15: 225-231.
 63. Fan T, Zhang M, Yang J, Zhu Z, Cao W, et al. (2025) Therapeutic cancer vaccines: advancements, challenges and prospects. *Signal Transduct Target Ther* 8:450.
 64. Wolde T, Bhardwaj V, Pandey V (2025) Current bioinformatics tools in precision oncology. *MedComm (Beijing)* 6: e70243.
 65. Moreira G, Maia R, Soares N, Ostolin T, Coura-Vital W, et al. (2024) Synthetic peptides selected by immunoinformatics as potential tools for the specific diagnosis of canine visceral leishmaniasis. *Microorganisms* 12: 906.
 66. Rácz A, Mihalovits LM, Bajusz D, Héberger K, Miranda-Quintana RA (2022) Molecular dynamics simulations and diversity selection by extended continuous similarity indices. *J Chem Inf Model* 62: 3415-3425.
 67. Mamuti M, Chen W, Jiang X (2023) Nanotechnology-assisted immunoengineering for cancer vaccines. *Adv NanoBiomed Res* 3: 2200080.
 68. Bravi B (2024) Development and use of machine learning algorithms in vaccine target selection. *npj Vaccines* 9: 15.
 69. Negrini S, De Palma R, Filaci G (2020) Anti-cancer immunotherapies targeting telomerase. *Cancers* 12: 2260.
 70. Ikeda H, Kawase K, Nishi T, Watanabe T, Takenaga K, et al. (2025) Immune evasion through mitochondrial transfer in the tumour microenvironment. *Nature* 638: 225-236.
 71. Lin F, Huang J, Zhu W, Jiang T, Guo J, et al. (2023) Prognostic value and immune landscapes of TERT promoter methylation in triple-negative breast cancer. *Front Immunol* 2023;14: 1218987.
 72. Petrina M, Martin J, Basta S (2021) Granulocyte macrophage colony-stimulating factor has come of age: from a vaccine adjuvant to antiviral immunotherapy. *Cytokine Growth Factor Rev* 59: 101-110.
 73. Achim E, Pîrlici E, Cristea C, Tertis M (2025) Design and efficacy of oncolytic viruses and antitumor vaccines: a dead end in the immunotherapy of pancreatic cancer? *Int J Mol Sci* 26: 9640.
 74. Rosenberg SA, Parkhurst MR, Robbins PF (2023) Adoptive cell transfer immunotherapy for patients with solid epithelial cancers. *Cancer Cell* 41: 646-648.
 75. Brunsvig PF, Guren TK, Nyakas M, Steinfeldt-Reisse CH, Rasch W, et al. (2020) Long-term outcomes of a phase I study with UV1, a second generation telomerase-based vaccine, in patients with advanced non-small cell lung cancer. *Front Immunol* 11: 572172.
 76. Sanchez-Mazas A, Nunes JM (2024) PGAE HLA Consortium of the 18th International HLA and Immunogenetics Workshop. The most frequent HLA alleles around the world: a fundamental synopsis. *Best Pract Res Clin Haematol* 37: 101559
 77. Cisneros-Villanueva M, Hidalgo-Pérez L, Rios-Romero M, Cedro-Tanda A, Ruiz-Villavicencio CA, et al. (2022) Cell-free DNA analysis in current cancer clinical trials: a review. *Br J Cancer* 126: 391-400.
 78. Bulut O, Kilic G, Domínguez-Andrés J (2022) Immune memory in aging: a wide perspective covering microbiota, brain, metabolism, and epigenetics. *Clin Rev Allergy Immunol* 63: 499-529.

79. Healy CM, Savas LS, Shegog R, Lunstroth R, Vernon SW (2022) Medical ethics principles underscore advocating for human papillomavirus vaccine. Hum Vaccin Immunother 18: 1989926.